Dechert advises M Ventures on Series A Financing for Scipio bioscience

Dechert advised M Ventures, in connection with a €6M Series A investment in Scipio bioscience, a Paris-based biotechnology company. 

M Ventures, the Amsterdam-based venture capital subsidiary of Merck, led an international syndicate of investors which also included the initial shareholders, Seventure Partners’ Quadrivium I fund (Paris-based) and High-Tech Gründerfonds (Bonn-based) as well as new international investors Financière Arbevel (Paris-based) and Invesere (Zürich-based).

Scipio bioscience, which had completed an initial €1.2 million seed financing round in 2017, is developing a new generation of single-cell sequencing solutions in the form of laboratory kits which will benefit research and clinical application. This new round of funding will enable Scipio bioscience to fuel the final development of its single-cell RNA-sequencing kit, as well as marketing and business development efforts to prepare for commercial launch in 2022.

The Dechert team advising M Ventures included:

• In corporate/venture: Anne-Charlotte Rivière, partner and Johann Gandilhon, associate
  
• In labor: Philippe Thomas, partner; Thibault Meiers, national partner; and Sophie Montagne, associate
  
• In intellectual property: Marie Fillon, national partner and Louis de Chezelles, associate
  
• In antitrust: Laurence Bary, national partner